肿瘤浸润淋巴细胞（TIL）是在肿瘤内浸润和积累的免疫细胞的一种亚型。研究证明，TIL 可用作癌症患者对免疫治疗反应的预后和预测标记。本综述探讨了 TIL 的现代知识、在癌症治疗中利用 TIL 的挑战和机遇，例如 TIL 情况下疗法的兴起、TIL 活性生物标志物的鉴定，以及用于分离和扩展 TIL 用于治疗用途的方法。重点介绍了不同癌症类型正在进行的临床试验和有希望的结果，包括黑色素瘤、卵巢癌和结直肠癌。它还侧重于通过识别对治疗癌症最有效的 TIL 特定子集以及开发增强 TIL 在肿瘤微环境中的功能和持久性的方法来改进基于 TIL 的疗法。本文概述了 TIL 疗法的现状、正在进行的研究及其效力的改进。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Tumor-infiltrating lymphocytes (TILs) are a subtype of immune cells that infiltrate and accumulate within tumors. Studies proved that TILs can be used as prognostic and predictive markers for cancer patients' responses to immunotherapy. This review explores the modern knowledge of TILs, the challenges and opportunities for utilizing TILs in cancer treatment, such as the rise of therapies under TIL circumstances, the identification of biomarkers for TIL activity, and methods used to isolate and expand TILs for therapeutic use. Ongoing clinical trials and promising results in different cancer types are highlighted, including melanoma, ovarian, and colorectal cancer. This also focuses on ongoing efforts to improve TIL-based therapies by identifying the specific subsets of TILs that are most effective in treating cancer and developing methods to increase the functionality and persistence of TILs in the tumor microenvironment. The article recapitulates the present state TILs therapy, ongoing research, and improvements to its potency.Copyright © 2024 Elsevier B.V. All rights reserved.